moderna news - Search News

Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

The Associated Press on MSN · 9d

Moderna lays out plan to slice research and development spending

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even.

STAT · 9d

Moderna touts research progress as it cuts R&D spending by $1.1 billion

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.

Investopedia · 9d

Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs

Moderna shares fell Thursday morning as the COVID vaccine maker said it plans to cut R&D spending by $1.1 billion over the next three years.

MT Newswires on MSN · 9d

Moderna to Cut Research, Development Spending, Prioritize New Product Approvals

Moderna (MRNA) said Thursday it plans to cut back on its research and development spending as the company looks to save costs and prioritize the launch of new products already in the pipeline. The drugmaker expects to reduce its annual R&D budget to a range between $3.

Investor's Business Daily on MSN5d

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

7don MSN

After Moderna's Shocking News, Is the Stock a Buy or a Sell?

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Down 13% in 1 Day, Is Moderna Stock in Trouble?

Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...

Moderna forecasts lower sales next year, shares near four-year low

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Behind the Scenes of Moderna's Latest Options Trends

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

8don MSN

Moderna Stock Keeps Falling. An Analyst's Downgrade Isn't Helping

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna Inc. stock underperforms Friday when compared to competitors

Shares of Moderna Inc. MRNA slipped 3.43% to $65.69 Friday, on what proved to be an all-around mixed trading session for the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics